Oncothyreon Inc.is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon’s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company’s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

-CEO Bob Kirkman found a way to renegogiate a deal with partner Merck KGaA a year ago which brought in $13 million, shifted the expense of manufacturing a cancer vaccine called Stimuvax off his books, and still retained a “double-digit” percentage royalty on sales if it becomes a marketed product.

-The company said its partner Merck KGaA started a late-stage study on Stimuvax as a potential lung cancer treatment.

-ONTY added 3.34%, to $5.57 today. It has a market cap of 142.93 million and has traded within a 52-week range of $0.77 and $7.77. ONTY is currently above its 20-day moving average of $5.11 and above its 100-day moving average of $5.00. It has near-term technical support in the $4.35 price area. If the shares can continue the recent rebound, we see overhead resistance around the $5.86 price levels. Technical indicator for the stock is buy.  Here is the chart: